Breaking News

Thursday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
ALX Oncology announces first patient dosed in Phase 2 trial of evorpacept » 07:46
08/11/22
08/11
07:46
08/11/22
07:46
ALXO

ALX Oncology

$12.78 /

+1.03 (+8.77%)

, MRK

Merck

$89.20 /

-0.32 (-0.36%)

, LLY

Eli Lilly

$304.62 /

+1.61 (+0.53%)

ALX Oncology (ALXO)…

ALX Oncology (ALXO) announced the initiation of a Phase 2 investigator-sponsored study of evorpacept, a next generation CD47 blocker, in combination with ERBITUX and KEYTRUDA, Merck's (MRK) anti-PD-1 therapy, in patients with refractory microsatellite stable metastatic colorectal cancer who have progressed on at least two lines of systemic therapy. This is an open-label, multi-center, single-arm phase 2 clinical trial. Eli Lilly (LLY) and Company and Merck, known as MSD outside the United States and Canada, will respectively provide ERBITUX and KEYTRUDA to support this study.

ShowHide Related Items >><<
MRK Merck
$89.20 /

-0.32 (-0.36%)

LLY Eli Lilly
$304.62 /

+1.61 (+0.53%)

ALXO ALX Oncology
$12.78 /

+1.03 (+8.77%)

ALXO ALX Oncology
$12.78 /

+1.03 (+8.77%)

08/09/22 Cantor Fitzgerald
ALX Oncology price target lowered to $32 from $60 at Cantor Fitzgerald
08/09/22 Credit Suisse
ALX Oncology price target lowered to $38 from $43 at Credit Suisse
06/06/22 Stifel
ALX Oncology price target lowered to $16 from $35 at Stifel
06/03/22 Piper Sandler
ALX's evorpacept best-in-class aong CD47-targeting agents, says Piper Sandler
MRK Merck
$89.20 /

-0.32 (-0.36%)

08/05/22 Truist
Global Blood could complement any oncology franchise, says Truist
07/29/22 Barclays
Merck price target raised to $101 from $97 at Barclays
07/27/22 H.C. Wainwright
Seagen price target raised to $200 from $170 at H.C. Wainwright
07/18/22 UBS
Merck price target raised to $98 from $76 at UBS
LLY Eli Lilly
$304.62 /

+1.61 (+0.53%)

08/05/22 Morgan Stanley
Eli Lilly recent weakness a buying opportunity, says Morgan Stanley
08/01/22 Jefferies
Concert Pharmaceuticals price target raised to $14 from $9.50 at Jefferies
07/27/22 Benchmark
AbCellera collaboration lowers reliance on Lilly, says Benchmark
07/18/22 Cowen
Cowen believes Global Pharma quarterly results will be strong
MRK Merck
$89.20 /

-0.32 (-0.36%)

LLY Eli Lilly
$304.62 /

+1.61 (+0.53%)

ALXO ALX Oncology
$12.78 /

+1.03 (+8.77%)

MRK Merck
$89.20 /

-0.32 (-0.36%)

LLY Eli Lilly
$304.62 /

+1.61 (+0.53%)

MRK Merck
$89.20 /

-0.32 (-0.36%)

LLY Eli Lilly
$304.62 /

+1.61 (+0.53%)

MRK Merck
$89.20 /

-0.32 (-0.36%)

LLY Eli Lilly
$304.62 /

+1.61 (+0.53%)

Tuesday
General news
Merck gives up gains after FDA announces impurity in diabetes drug  14:26
08/09/22
08/09
14:26
08/09/22
14:26
MRK

Merck

$90.09 /

+1.62 (+1.83%)

 
ShowHide Related Items >><<
MRK Merck
$90.09 /

+1.62 (+1.83%)

MRK Merck
$90.09 /

+1.62 (+1.83%)

08/05/22 Truist
Global Blood could complement any oncology franchise, says Truist
07/29/22 Barclays
Merck price target raised to $101 from $97 at Barclays
07/27/22 H.C. Wainwright
Seagen price target raised to $200 from $170 at H.C. Wainwright
07/18/22 UBS
Merck price target raised to $98 from $76 at UBS
MRK Merck
$90.09 /

+1.62 (+1.83%)

MRK Merck
$90.09 /

+1.62 (+1.83%)

MRK Merck
$90.09 /

+1.62 (+1.83%)

MRK Merck
$90.09 /

+1.62 (+1.83%)

Hot Stocks
FDA finds nitrosamine impurity in Merck diabetes drug Januvia » 14:24
08/09/22
08/09
14:24
08/09/22
14:24
MRK

Merck

$90.07 /

+1.6 (+1.81%)

The FDA said it recently…

The FDA said it recently became aware of a nitrosamine impurity, Nitroso-STG-19, in certain samples of Merck's Januvia, also known as sitagliptin, a medicine used to treat type 2 diabetes mellitus. "To avoid a shortage and help ensure patients have access to an adequate supply of the medicine, FDA will not object to the temporary distribution of sitagliptin containing NTTP above the acceptable intake limit of 37 ng per day, and up to 246.7 ng per day," the agency said in a statement. Sitagliptin is a prescription drug used to control high blood sugar in patients with type 2 diabetes mellitus. The FDA recommends prescribers continue to use sitagliptin "when clinically appropriate to prevent a gap in patient treatment." Reference Link

ShowHide Related Items >><<
MRK Merck
$90.07 /

+1.6 (+1.81%)

MRK Merck
$90.07 /

+1.6 (+1.81%)

08/05/22 Truist
Global Blood could complement any oncology franchise, says Truist
07/29/22 Barclays
Merck price target raised to $101 from $97 at Barclays
07/27/22 H.C. Wainwright
Seagen price target raised to $200 from $170 at H.C. Wainwright
07/18/22 UBS
Merck price target raised to $98 from $76 at UBS
MRK Merck
$90.07 /

+1.6 (+1.81%)

MRK Merck
$90.07 /

+1.6 (+1.81%)

MRK Merck
$90.07 /

+1.6 (+1.81%)

MRK Merck
$90.07 /

+1.6 (+1.81%)

Over a week ago
Recommendations
Global Blood could complement any oncology franchise, says Truist » 13:18
08/05/22
08/05
13:18
08/05/22
13:18
GBT

Global Blood Therapeutics

$66.20 /

+18.21 (+37.95%)

, PFE

Pfizer

$49.41 /

-0.465 (-0.93%)

, MRK

Merck

$87.06 /

+0.16 (+0.18%)

, BMY

Bristol-Myers

$72.15 /

+0.025 (+0.03%)

, NVO

Novo Nordisk

$103.06 /

-1.465 (-1.40%)

, NVS

Novartis

$85.39 /

+0.125 (+0.15%)

, VRTX

Vertex Pharmaceuticals

$286.79 /

+12.83 (+4.68%)

After getting inbound…

After getting inbound inquires from investors on the WSJ article about Pfizer (PFE) being in advanced talks to buy Global Blood Therapeutics (GBT) for $5B, Truist analyst Joon Lee noted that Pfizer does not have a sickle cell franchise, but said that Oxbryta and pipeline drug GBT601 "should be more broadly considered as anemia drugs" so Global Blood "could be a good complement to any pharma" company with an oncology franchise. Merck (MRK), Bristol-Myers (BMY), Novo Nordisk (NVO), Vertex (VRTX) and Novartis (NVS) may also make sense as an acquirer, added Lee. Regarding the reported valuation of $5B, a takeout price would be in the $59 range assuming pending options, convertible notes and RSUs are included, but if based only on the basic share count figure, that market cap value would equate to a $77 per share price, said the analyst, who awaits further clarity. Lee has a Buy rating and $50 price target on Global Blood shares, which are up $17.70, or 37%, to $65.69 in afternoon trading.

ShowHide Related Items >><<
VRTX Vertex Pharmaceuticals
$286.79 /

+12.83 (+4.68%)

PFE Pfizer
$49.41 /

-0.465 (-0.93%)

NVS Novartis
$85.39 /

+0.125 (+0.15%)

NVO Novo Nordisk
$103.06 /

-1.465 (-1.40%)

MRK Merck
$87.06 /

+0.16 (+0.18%)

GBT Global Blood Therapeutics
$66.20 /

+18.21 (+37.95%)

BMY Bristol-Myers
$72.15 /

+0.025 (+0.03%)

GBT Global Blood Therapeutics
$66.20 /

+18.21 (+37.95%)

08/04/22 Truist
Truist sees Novartis, Vertex as logical suitors for Global Blood
06/28/22 JPMorgan
Global Blood Therapeutics price target lowered to $36 from $39 at JPMorgan
05/11/22 Wedbush
Global Blood Therapeutics added to Best Ideas List at Wedbush
05/05/22 Oppenheimer
Global Blood Therapeutics price target lowered to $71 from $86 at Oppenheimer
PFE Pfizer
$49.41 /

-0.465 (-0.93%)

08/01/22 Jefferies
Concert Pharmaceuticals price target raised to $14 from $9.50 at Jefferies
08/01/22 Barclays
Pfizer price target raised to $52 from $50 at Barclays
07/22/22 Piper Sandler
Piper says Pfizer expansion into Crohn's ups conviction in Prometheus drug
07/18/22 Cowen
Cowen believes Global Pharma quarterly results will be strong
MRK Merck
$87.06 /

+0.16 (+0.18%)

07/29/22 Barclays
Merck price target raised to $101 from $97 at Barclays
07/27/22 H.C. Wainwright
Seagen price target raised to $200 from $170 at H.C. Wainwright
07/18/22 UBS
Merck price target raised to $98 from $76 at UBS
07/12/22 H.C. Wainwright
H.C. Wainwright says Bellus set for 'show down' against Merck's gefapixant
BMY Bristol-Myers
$72.15 /

+0.025 (+0.03%)

08/05/22 Jefferies
Jefferies downgrades Compugen to Hold with cash likely becoming 'growing issue'
08/04/22 Stifel
Compugen price target lowered to $5 from $12 at Stifel
07/28/22 JPMorgan
Bristol-Myers price target raised to $85 from $80 at JPMorgan
07/20/22 Canaccord
Canaccord starts Arcellx at Buy, sees 'best-in-class' potential
NVO Novo Nordisk
$103.06 /

-1.465 (-1.40%)

08/04/22 Barclays
Novo Nordisk price target lowered to DKK 825 from DKK 875 at Barclays
08/03/22 Piper Sandler
Piper says Altimmune selloff related to Novo continuing Phase 3 SELECT trial
07/15/22 Morgan Stanley
Novo Nordisk upgraded to Overweight from Equal Weight at Morgan Stanley
06/28/22 UBS
Novo Nordisk downgraded to Sell from Neutral at UBS
NVS Novartis
$85.39 /

+0.125 (+0.15%)

07/20/22 JPMorgan
Novartis price target raised to CHF 81 from CHF 80 at JPMorgan
07/20/22 Piper Sandler
Piper adjusts Ionis' Spinraza royalties estimate following Biogen report
06/29/22 Deutsche Bank
Novartis price target lowered to CHF 75 from CHF 80 at Deutsche Bank
VRTX Vertex Pharmaceuticals
$286.79 /

+12.83 (+4.68%)

08/05/22 H.C. Wainwright
Vertex Pharmaceuticals price target raised to $300 from $275 at H.C. Wainwright
08/05/22 Barclays
Vertex Pharmaceuticals price target raised to $307 from $291 at Barclays
07/26/22 Piper Sandler
Vertex Pharmaceuticals price target raised to $256 from $242 at Piper Sandler
VRTX Vertex Pharmaceuticals
$286.79 /

+12.83 (+4.68%)

PFE Pfizer
$49.41 /

-0.465 (-0.93%)

NVS Novartis
$85.39 /

+0.125 (+0.15%)

NVO Novo Nordisk
$103.06 /

-1.465 (-1.40%)

MRK Merck
$87.06 /

+0.16 (+0.18%)

GBT Global Blood Therapeutics
$66.20 /

+18.21 (+37.95%)

BMY Bristol-Myers
$72.15 /

+0.025 (+0.03%)

PFE Pfizer
$49.41 /

-0.465 (-0.93%)

NVS Novartis
$85.39 /

+0.125 (+0.15%)

NVO Novo Nordisk
$103.06 /

-1.465 (-1.40%)

MRK Merck
$87.06 /

+0.16 (+0.18%)

GBT Global Blood Therapeutics
$66.20 /

+18.21 (+37.95%)

BMY Bristol-Myers
$72.15 /

+0.025 (+0.03%)

VRTX Vertex Pharmaceuticals
$286.79 /

+12.83 (+4.68%)

PFE Pfizer
$49.41 /

-0.465 (-0.93%)

NVS Novartis
$85.39 /

+0.125 (+0.15%)

NVO Novo Nordisk
$103.06 /

-1.465 (-1.40%)

MRK Merck
$87.06 /

+0.16 (+0.18%)

GBT Global Blood Therapeutics
$66.20 /

+18.21 (+37.95%)

BMY Bristol-Myers
$72.15 /

+0.025 (+0.03%)

VRTX Vertex Pharmaceuticals
$286.79 /

+12.83 (+4.68%)

PFE Pfizer
$49.41 /

-0.465 (-0.93%)

NVO Novo Nordisk
$103.06 /

-1.465 (-1.40%)

MRK Merck
$87.06 /

+0.16 (+0.18%)

BMY Bristol-Myers
$72.15 /

+0.025 (+0.03%)

Hot Stocks
AstraZeneca, Merck: EC approves LYNPARZA to treat BRCA1/2 mutations » 06:51
08/04/22
08/04
06:51
08/04/22
06:51
MRK

Merck

$87.59 /

-0.03 (-0.03%)

, AZN

AstraZeneca

$65.31 /

+0.055 (+0.08%)

AstraZeneca (AZN) and…

AstraZeneca (AZN) and Merck (MRK) announced that the European Commission has approved LYNPARZA as monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients with germline BRCA1/2 mutations (gBRCAm), who have human epidermal growth factor receptor 2-negative high-risk early breast cancer previously treated with neoadjuvant or adjuvant chemotherapy.

ShowHide Related Items >><<
MRK Merck
$87.59 /

-0.03 (-0.03%)

AZN AstraZeneca
$65.31 /

+0.055 (+0.08%)

MRK Merck
$87.59 /

-0.03 (-0.03%)

07/29/22 Barclays
Merck price target raised to $101 from $97 at Barclays
07/27/22 H.C. Wainwright
Seagen price target raised to $200 from $170 at H.C. Wainwright
07/18/22 UBS
Merck price target raised to $98 from $76 at UBS
07/12/22 H.C. Wainwright
H.C. Wainwright says Bellus set for 'show down' against Merck's gefapixant
AZN AstraZeneca
$65.31 /

+0.055 (+0.08%)

08/01/22 JPMorgan
AstraZeneca price target raised to 12,500 GBp from 12,000 GBp at JPMorgan
08/01/22 Deutsche Bank
AstraZeneca price target raised to 12,000 GBp from 11,500 GBp at Deutsche Bank
07/29/22 Stifel
Zentalis loses top competitor with AstraZeneca discontinuation, says Stifel
07/12/22 Citi
AstraZeneca price target raised to 13,000 GBp from 10,500 GBp at Citi
MRK Merck
$87.59 /

-0.03 (-0.03%)

AZN AstraZeneca
$65.31 /

+0.055 (+0.08%)

MRK Merck
$87.59 /

-0.03 (-0.03%)

AZN AstraZeneca
$65.31 /

+0.055 (+0.08%)

MRK Merck
$87.59 /

-0.03 (-0.03%)

AZN AstraZeneca
$65.31 /

+0.055 (+0.08%)

MRK Merck
$87.59 /

-0.03 (-0.03%)

AZN AstraZeneca
$65.31 /

+0.055 (+0.08%)

Hot Stocks
AstraZeneca's lynparza approved in EU for early breast cancer therapy » 06:17
08/04/22
08/04
06:17
08/04/22
06:17
AZN

AstraZeneca

$65.31 /

+0.055 (+0.08%)

, MRK

Merck

$87.59 /

-0.03 (-0.03%)

AstraZeneca (AZN) and…

AstraZeneca (AZN) and MSD's (MRK) Lynparza, or olaparib, has been approved in the European Union as monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients with germline BRCA1/2 mutations, who have human epidermal growth factor receptor 2 (HER2)-negative high-risk early breast cancer previously treated with neoadjuvant or adjuvant chemotherapy. This approval by the European Commission was based on results from the OlympiA Phase III trial published in The New England Journal of Medicine in June 2021 and follows the recommendation for approval in the EU by the Committee for Medicinal Products for Human Use of Lynparza in this setting.1 In the trial, Lynparza demonstrated a statistically significant and clinically meaningful improvement in invasive disease-free survival (iDFS), reducing the risk of invasive breast cancer recurrences, new cancers, or death by 42% versus placebo. Lynparza also demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS), reducing the risk of death by 32% versus placebo (based on a HR of 0.68; 98.5% CI 0.47-0.97; p&#61;0.009). The safety and tolerability profile of Lynparza in this trial was in line with that observed in prior clinical trials. Reference Link

ShowHide Related Items >><<
MRK Merck
$87.59 /

-0.03 (-0.03%)

AZN AstraZeneca
$65.31 /

+0.055 (+0.08%)

AZN AstraZeneca
$65.31 /

+0.055 (+0.08%)

08/01/22 JPMorgan
AstraZeneca price target raised to 12,500 GBp from 12,000 GBp at JPMorgan
08/01/22 Deutsche Bank
AstraZeneca price target raised to 12,000 GBp from 11,500 GBp at Deutsche Bank
07/29/22 Stifel
Zentalis loses top competitor with AstraZeneca discontinuation, says Stifel
07/12/22 Citi
AstraZeneca price target raised to 13,000 GBp from 10,500 GBp at Citi
MRK Merck
$87.59 /

-0.03 (-0.03%)

07/29/22 Barclays
Merck price target raised to $101 from $97 at Barclays
07/27/22 H.C. Wainwright
Seagen price target raised to $200 from $170 at H.C. Wainwright
07/18/22 UBS
Merck price target raised to $98 from $76 at UBS
07/12/22 H.C. Wainwright
H.C. Wainwright says Bellus set for 'show down' against Merck's gefapixant
MRK Merck
$87.59 /

-0.03 (-0.03%)

AZN AstraZeneca
$65.31 /

+0.055 (+0.08%)

MRK Merck
$87.59 /

-0.03 (-0.03%)

AZN AstraZeneca
$65.31 /

+0.055 (+0.08%)

MRK Merck
$87.59 /

-0.03 (-0.03%)

AZN AstraZeneca
$65.31 /

+0.055 (+0.08%)

MRK Merck
$87.59 /

-0.03 (-0.03%)

AZN AstraZeneca
$65.31 /

+0.055 (+0.08%)

Hot Stocks
Merck, Eisai provide update on Phase 3 LEAP-002 trial evaluating KEYTRUDA » 06:49
08/03/22
08/03
06:49
08/03/22
06:49
MRK

Merck

$87.62 /

-0.92 (-1.04%)

, ESALY

Eisai

$45.20 /

-1.011 (-2.19%)

Merck (MRK) and Eisai…

Merck (MRK) and Eisai (ESALY) announced that the Phase 3 LEAP-002 trial investigating KEYTRUDA, Merck's anti-PD-1 therapy, plus LENVIMA, the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai, versus LENVIMA monotherapy did not meet its dual primary endpoints of overall survival and progression-free survival as a first-line treatment for patients with unresectable hepatocellular carcinoma. There were trends toward improvement in OS and PFS for patients who received KEYTRUDA plus LENVIMA versus LENVIMA monotherapy; however, these results did not meet statistical significance per the pre-specified statistical plan. The median OS of the LENVIMA monotherapy arm in LEAP-002 was longer than that observed in previously reported clinical trials evaluating LENVIMA monotherapy in uHCC. The safety profile of KEYTRUDA plus LENVIMA was consistent with previously reported data on the combination. Merck and Eisai plan to present these data at an upcoming medical conference.

ShowHide Related Items >><<
MRK Merck
$87.62 /

-0.92 (-1.04%)

ESALY Eisai
$45.20 /

-1.011 (-2.19%)

MRK Merck
$87.62 /

-0.92 (-1.04%)

07/29/22 Barclays
Merck price target raised to $101 from $97 at Barclays
07/27/22 H.C. Wainwright
Seagen price target raised to $200 from $170 at H.C. Wainwright
07/18/22 UBS
Merck price target raised to $98 from $76 at UBS
07/12/22 H.C. Wainwright
H.C. Wainwright says Bellus set for 'show down' against Merck's gefapixant
ESALY Eisai
$45.20 /

-1.011 (-2.19%)

07/21/22 Truist
Biogen price target lowered to $270 from $320 at Truist
04/08/22 William Blair
CMS decision to substantially limit Biogen opportunity, says William Blair
03/28/22 BofA
Biogen price target lowered to $225 from $230 at BofA
01/13/22 Citi
Eisai downgraded to Neutral from Buy at Citi
MRK Merck
$87.62 /

-0.92 (-1.04%)

MRK Merck
$87.62 /

-0.92 (-1.04%)

ESALY Eisai
$45.20 /

-1.011 (-2.19%)

MRK Merck
$87.62 /

-0.92 (-1.04%)

ESALY Eisai
$45.20 /

-1.011 (-2.19%)

MRK Merck
$87.62 /

-0.92 (-1.04%)

Hot Stocks
Merck says Phase 3 KEYNOTE-921 trial did not meet dual primary endpoints » 06:42
08/03/22
08/03
06:42
08/03/22
06:42
MRK

Merck

$87.62 /

-0.92 (-1.04%)

Merck announced that the…

Merck announced that the Phase 3 KEYNOTE-921 trial evaluating KEYTRUDA in combination with chemotherapy compared to chemotherapy alone did not meet its dual primary endpoints of overall survival, or OS, and radiographic progression-free survival, or rPFS, for the treatment of patients with metastatic castration-resistant prostate cancer, or mCRPC. "In the study, there were modest trends toward an improvement in both OS and rPFS for patients who received KEYTRUDA plus chemotherapy compared with chemotherapy alone; however, these results did not meet statistical significance per the pre-specified statistical plan. The safety profile of KEYTRUDA in this trial was consistent with that observed in previously reported studies. Results will be presented at an upcoming medical meeting," the company stated. "Results from this study serve as an important reminder that metastatic prostate cancer remains very difficult to treat, and more research is needed. We will continue to advance our clinical development program to evaluate KEYTRUDA-based combinations and novel candidates for patients with this disease," said Dr. Eliav Barr, senior vice president, head of global clinical development and chief medical officer, Merck Research Laboratories.

ShowHide Related Items >><<
MRK Merck
$87.62 /

-0.92 (-1.04%)

MRK Merck
$87.62 /

-0.92 (-1.04%)

07/29/22 Barclays
Merck price target raised to $101 from $97 at Barclays
07/27/22 H.C. Wainwright
Seagen price target raised to $200 from $170 at H.C. Wainwright
07/18/22 UBS
Merck price target raised to $98 from $76 at UBS
07/12/22 H.C. Wainwright
H.C. Wainwright says Bellus set for 'show down' against Merck's gefapixant
MRK Merck
$87.62 /

-0.92 (-1.04%)

MRK Merck
$87.62 /

-0.92 (-1.04%)

MRK Merck
$87.62 /

-0.92 (-1.04%)

MRK Merck
$87.62 /

-0.92 (-1.04%)

Hot Stocks
ALX Oncology's evorpacept receives FTD from FDA » 07:10
08/01/22
08/01
07:10
08/01/22
07:10
ALXO

ALX Oncology

$9.67 /

-1.38 (-12.49%)

, MRK

Merck

$89.42 /

-0.42 (-0.47%)

ALX Oncology (ALXO)…

ALX Oncology (ALXO) announced that the U.S. Food and Drug Administration, FDA, has granted Fast Track designation, FTD, to evorpacept, a next generation CD47 blocker, in combination with KEYTRUDA, Merck's (MRK) anti-PD-1 therapy, for the first-line treatment of adult patients with PD-L1 positive advanced head and neck squamous cell carcinoma, HNSCC. The FDA's decision is informed by the results of ALX Oncology's phase 1 clinical trial, ASPEN-01, that showed preliminary antitumor activity and a favorable safety profile in checkpoint inhibitor-naive patients with second-line or greater advanced HNSCC treated with evorpacept and pembrolizumab. "The FDA's Fast Track designation for the first-line treatment of HNSCC with evorpacept in combination with pembrolizumab builds upon evorpacept's prior Fast Track designation in the first-line HNSCC population in combination with pembrolizumab and standard chemotherapy highlighting the potential clinical utility of evorpacept in this difficult-to-treat disease," said Sophia Randolph, M.D., Ph.D., Chief Medical Officer, ALX Oncology. "We are pleased by the patient enrollment progress being made across our HNSCC phase 2 program as we seek to advance evorpacept to help patients living with this disease."

ShowHide Related Items >><<
MRK Merck
$89.42 /

-0.42 (-0.47%)

ALXO ALX Oncology
$9.67 /

-1.38 (-12.49%)

ALXO ALX Oncology
$9.67 /

-1.38 (-12.49%)

06/06/22 Stifel
ALX Oncology price target lowered to $16 from $35 at Stifel
06/03/22 Piper Sandler
ALX's evorpacept best-in-class aong CD47-targeting agents, says Piper Sandler
05/18/22 Piper Sandler
ALX Oncology price target lowered to $48 from $70 at Piper Sandler
03/14/22 Cantor Fitzgerald
ALX Oncology price target lowered to $60 from $103 at Cantor Fitzgerald
MRK Merck
$89.42 /

-0.42 (-0.47%)

07/29/22 Barclays
Merck price target raised to $101 from $97 at Barclays
07/27/22 H.C. Wainwright
Seagen price target raised to $200 from $170 at H.C. Wainwright
07/18/22 UBS
Merck price target raised to $98 from $76 at UBS
07/12/22 H.C. Wainwright
H.C. Wainwright says Bellus set for 'show down' against Merck's gefapixant
MRK Merck
$89.42 /

-0.42 (-0.47%)

ALXO ALX Oncology
$9.67 /

-1.38 (-12.49%)

MRK Merck
$89.42 /

-0.42 (-0.47%)

MRK Merck
$89.42 /

-0.42 (-0.47%)

MRK Merck
$89.42 /

-0.42 (-0.47%)

Recommendations
Merck price target raised to $101 from $97 at Barclays » 06:58
07/29/22
07/29
06:58
07/29/22
06:58
MRK

Merck

$89.84 /

-1.35 (-1.48%)

Barclays analyst Carter…

Barclays analyst Carter Gould raised the firm's price target on Merck to $101 from $97 and keeps an Overweight rating on the shares. The company reported "another beat and raise," driven by Keytruda and Gardasil, Gould tells investors in a research note.

ShowHide Related Items >><<
MRK Merck
$89.84 /

-1.35 (-1.48%)

MRK Merck
$89.84 /

-1.35 (-1.48%)

07/27/22 H.C. Wainwright
Seagen price target raised to $200 from $170 at H.C. Wainwright
07/18/22 UBS
Merck price target raised to $98 from $76 at UBS
07/12/22 H.C. Wainwright
H.C. Wainwright says Bellus set for 'show down' against Merck's gefapixant
07/08/22 Morgan Stanley
Merck price target raised to $88 from $87 at Morgan Stanley
MRK Merck
$89.84 /

-1.35 (-1.48%)

MRK Merck
$89.84 /

-1.35 (-1.48%)

MRK Merck
$89.84 /

-1.35 (-1.48%)

MRK Merck
$89.84 /

-1.35 (-1.48%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.